In Brief: BRCA1 patent infringement lawsuits
This article was originally published in The Gray Sheet
Executive Summary
BRCA1 patent infringement lawsuits: Myriad Genetics sues OncorMed in Salt Lake City, Utah federal court, alleging that the firm infringes Myriad's patent No. 5,693,473, entitled "17q-Linked Breast and Ovarian Cancer Susceptibility Gene." Myriad filed the suit Dec. 2, the same day the company was issued the patent. The complaint follows OncorMed's Nov. 17 lawsuit alleging that Myriad infringes its own BRCA1-related patent ("The Gray Sheet" Dec. 1, I&W-6). Both firms market tests for detecting mutations in the BRCA1 and BRCA2 genes...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.